Literature DB >> 2163315

Evidence that an iodolactone mediates the inhibitory effect of iodide on thyroid cell proliferation but not on adenosine 3',5'-monophosphate formation.

A Dugrillon1, G Bechtner, W M Uedelhoven, P C Weber, R Gärtner.   

Abstract

Iodolactone (6-iodo-8,11,14-eicosatrienoic-delta-lactone), an iodinated derivative of arachidonic acid, was found to be synthesized in rat thyroid slices; however, the physiological role of this compound is still unknown. We tried to detect iodolactone in isolated porcine thyroid follicles and investigated the effects of in vitro synthesized iodolactone on epidermal growth factor-induced thyroid cell proliferation and TSH-induced cAMP formation. In vitro synthesis of iodolactone was performed with lactoperoxidase-catalyzed iodination of arachidonic acid in the presence of trace amounts of [125I]- and [3H]arachidonic acid. After purification by silica gel chromatography, HPLC of the reaction products revealed one main peak containing trace amounts of both [125I]- and [3H]arachidonic acid. With gas chromatography-mass spectrometry (GC-MS) a molecular mass of 391 m/z, corresponding to the derivatization product of iodolactone, was found. An ethanol-chloroform extract of isolated thyroid follicles preincubated with KI (10 microM) and arachidonic acid (1 microM) revealed peaks in HPLC and GC comparable with those of in vitro synthesized iodolactone. This indicates the ability of thyroid follicles to form iodolactone. Iodolactone (0.1-1.0 microM) dose-dependently inhibited epidermal growth factor-induced thyroid cell growth. This growth-inhibiting effect of iodolactone was 50-fold more pronounced than the inhibitory effect of KI (4 X 10(-5) microM) on thyroid cell proliferation. In contrast to the effect of iodide, the inhibitory effect of iodolactone on thyroid cell growth could not be abolished by methimazole (1 mM). Basal as well as TSH (0.5 U/liter)-induced cAMP formation were not changed by iodolactone. These experiments suggest a physiological role of iodolactone as a mediator of the known inhibitory effect of iodide on thyroid growth.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2163315     DOI: 10.1210/endo-127-1-337

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  Molecular pathogenesis of nodular goiter.

Authors:  Ralf Paschke
Journal:  Langenbecks Arch Surg       Date:  2011-04-14       Impact factor: 3.445

Review 2.  Is iodine a gatekeeper of the integrity of the mammary gland?

Authors:  Carmen Aceves; Brenda Anguiano; Guadalupe Delgado
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-04       Impact factor: 2.673

3.  Longchain serum fatty acids and risk of thyroid cancer: a population-based case-control study in Norway.

Authors:  J P Berg; E Glattre; T Haldorsen; A T Høstmark; I G Bay; A F Johansen; E Jellum
Journal:  Cancer Causes Control       Date:  1994-09       Impact factor: 2.506

Review 4.  S1P and plasmalogen derived fatty aldehydes in cellular signaling and functions.

Authors:  David L Ebenezer; Panfeng Fu; Ramaswamy Ramchandran; Alison W Ha; Vijay Putherickal; Tara Sudhadevi; Anantha Harijith; Fabian Schumacher; Burkhard Kleuser; Viswanathan Natarajan
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-03-12       Impact factor: 4.698

5.  Apoptosis of NOD.H2 h4 thyrocytes by low concentrations of iodide is associated with impaired control of oxidative stress.

Authors:  Panayota Kolypetri; George Carayanniotis
Journal:  Thyroid       Date:  2014-05-28       Impact factor: 6.568

6.  Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone.

Authors:  Mario Nava-Villalba; Rosa E Nuñez-Anita; Alexander Bontempo; Carmen Aceves
Journal:  Mol Cancer       Date:  2015-09-17       Impact factor: 27.401

7.  Prognostic Significance of Sodium Iodide Symporter and Deiodinase Enzymes mRNA Expression in Gastric Cancer.

Authors:  Alok Mishra; Ashutosh Shrivastava
Journal:  Int J Appl Basic Med Res       Date:  2020-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.